[go: up one dir, main page]

EP1235570A2 - Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics - Google Patents

Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics

Info

Publication number
EP1235570A2
EP1235570A2 EP00982461A EP00982461A EP1235570A2 EP 1235570 A2 EP1235570 A2 EP 1235570A2 EP 00982461 A EP00982461 A EP 00982461A EP 00982461 A EP00982461 A EP 00982461A EP 1235570 A2 EP1235570 A2 EP 1235570A2
Authority
EP
European Patent Office
Prior art keywords
antipsychotic
methyl
indol
dioxino
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00982461A
Other languages
German (de)
French (fr)
Inventor
Karen Lovell Marquis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of EP1235570A2 publication Critical patent/EP1235570A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to therapeutic combinations of (S)-2- (benzylaminomethyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one, a partial agonist of the dopamine D2/D3 receptors, and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of psychotic disorders.
  • Psychoses are serious mental illnesses characterized by defective or lost contact with reality. These disorders are characterized by a variety of symptoms which are classified as positive symptoms (disordered thought, hallucinations, and delusions), negative symptoms (social withdrawal and unresponsiveness), and cognitive deficits.
  • Neuroleptics or antipsychotics can be used to treat schizophrenia and other related psychotic disorders by blocking the dopaminergic neurotransmission in the central nervous system. Neuroleptics are used widely to treat the "positive" symptoms of schizophrenia. However, many of these drugs are not considered to be effective for the treatment of "negative” symptoms of schizophrenia and may in fact exacerbate these symptoms because of the dopaminergic blockade associated with their mechanism of action. Cognitive deficits associated with schizophrenia, such as distractability, and executive skills such as a working memory and ability to plan, are also believed to be negatively effected by the blockade of dopamine receptors.
  • these neuroleptics have important side effects such as akathisia, dystonia, Parkinsonism dyskinesia and late dyskinesia and the like, which are caused by blocking the dopaminergic neurotransmission.
  • Anticholinergic agents such as Cogentin®, have been used to reduce Parkinson-like side effects, but also cause side effects such as mental and/or physical impairment, tachycardia, dysuria and gastrointestinal symptoms.
  • Some partial dopamine agonists with relatively high intrinsic activity have been shown to have effectiveness against the negative symptoms of schizophrenia. It has been hypothesized that in this respect, some intrinsic activity is desirable to optimize the treatment of negative symptoms while minimizing side effects.
  • New combination drug therapies may be useful for treatment of patients. It is greatly desired to optimize the beneficial properties of both drugs, while minimizing the side effects associated with the drugs when given alone. Applicants have found useful therapeutic combination for the treatment of psychotic disorders.
  • Figure 1 is a schematic representation of the effect of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) on haloperidol- induced catalepsy in rats at 60 minutes after drug treatment, the time point of greatest reversal as measured by seconds spent in catelepsy over a dose range of 0.003 to 3 mg/kg s.c. of agent.
  • the data are means + SEM.
  • Figure 2 is a schematic representation of the ability of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) to induce catalepsy in rats as measured by seconds spent in catelepsy over a dose range of 0.003 to 3 mg/kg s.c. of agent.
  • the data are means + SEM.
  • Figure 3 is a schematic representation of the effect of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) to reverse d-amphetamine induced hyperactivity in mice.
  • the data are expressed as a percentage of the activity level (horizontal activity counts) observed in mice treated with d-amphetamine alone for eight doses ranging from 0.0001 to 1 mg kg s.c. of agent.
  • the data are presented as means + SEM.
  • composition comprising (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]- indol-8-one, or pharmaceutical salts thereof, and one or more antipsychotic agents.
  • Pharmaceutically acceptable salts include acid addition salts such as hydrochloric, fumaric, maleic, citric or succinic.
  • antipsychotic agent or neuroleptic agent includes those antipsychotics which work as a full antagonist of the dopamine D2 receptor and include both typical and atypical antipsychotics.
  • Representative antipsychotic agents that are commercially available or known to those skilled in the art and include, but are not limited to:
  • Chlorpromazine or 2-chloro-N,N-dimethyl- 1 OH-phenothiazine- 10-propan- amine, is described in U.S. Patent No. 2,645,640, which is incorporated by reference herein in its entirety.
  • Trifluoperazine or 10- [3-(4-methyl- 1 -piperazinyl)-propyl]-2-(trifluoro- methyl)- 1 OH-phenothiazine is described in GB 813,861 which is incorporated by reference herein in its entirety.
  • Perphenazine or 4-[3-(2-chloro-10H-phenothiazin-l-yl)propyl]-l-piperazine- ethanol, is described in U.S. Patent No. 2,766,235, which is incorporated by reference herein in its entirety.
  • Clozapine, or 8-chloro-l l-(4-methyl-l-piperazinyl)-5H-dibenzo[b,e]-[l,4]- diazepine is described in U.S. Patent No. 3,539,573, which is incorporated by reference herein in its entirety.
  • Haloperidol or 4-[4-(4-chlorophenyl)-4-hydroxy-l-piperidinyl]-l-(4-fluoro- phenyl)-l-butanone is described in U.S. Patent No. 3,438,991, which is incorporated by reference herein in its entirety.
  • Thiothixene or N,N-dimethyl-9-[3-(4-methyl- 1 -piperazinyl)-propylidene-9H- thioxanthene-2-sulfanamide is described in U.S. Patent No. 3,310,553, which is incorporated by reference herein in its entirety.
  • Sulphide, or 5-(aminosulfonyl)-N-[(l-ethyl-2-pyrolidinyl)methyl]-2-meth- oxybenzamide is described in U.S. Patent No. 3,342,826, which is incorporated by reference herein in its entirety.
  • Amisulpiride or 4-amino-N-[(l-ethyl-2-pyrrolidin-yl)methyl]-5-(ethyl- sulfonyl)-2-methoxybezamide, is described in U.S. Patent No. 4,401,822, which is incorporated by reference herein in its entirety.
  • Risperidone or 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)piperidino]-ethyl]- imidazolidin-2-one, is described in U.S. Patent No. 4,804,663, which is incorporated by reference herein in its entirety.
  • Seroquel or 1 l-[4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyl]dibenzo[b,f]- [l,4]thiazepine, preparation is described in EP 240228, which is incorporated by reference herein in its entirety.
  • (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4- dioxino[2,3-e]indol-8-one in combination with one or more antipsychotic agents is useful for the treatment or prevention of psychotic disorders associated with altered neurotransmission activity of the dopaminergic system in the central nervous system such as schizophrenia, schizoaffective disorder, acute mania, and depression with psychotic features, while eliminating or minimizing certain side affects associated with said antipsychotics when taken alone such as akathisia, dystonia, Parkinsonism dyskinesia and late dyskinesia and the like.
  • This invention also provides a product comprising (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one and an antipsychotic agent as a combined preparation for simultaneous, separate or sequential administration to treat a patient suffering from a psychotic disorder.
  • Combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4-di- oxino[2,3-e]indol-8-one and one or more antipsychotics hereinafter referred to as "combinations” may be administered simultaneously, in the same or different pharmaceutical formulation, or sequentially.
  • the timing of the sequential administration should preserve the advantageous effects of the combination and said timing can be determined by a skilled practitioner.
  • a therapeutically acceptable amount of the combination will be understood to be an amount which treats, inhibits, prevents or ameliorates one or more symptoms of the psychotic disorder in question, preferably with fewer side effects than those associated with the administration of the antipsychotic agent alone.
  • the dosages of each of the drugs in the combination must be determined by a physician and will depend upon the specific psychotic disorder, as well as the size, age and response pattern of the patient. Dosage guidelines are provided here. For the combination, the dosage guideline for each of the drugs of the combination would be considered.
  • suitable doses of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro- 7H-l,4-dioxino[2,3-e]indol-8-one range from about 0.5 mg per day to about 100 mg per day, and more preferably from about 1 to about 50 mg per day.
  • a suitable dose of antipsychotic agent will be in the range recommended by the manufacturer. The following guidelines are provided for some preferred antipsychotics of the present invention:
  • Chlorpromazine from about 300 to about 800 mg per day
  • Mesoridazine from about 100 to about 400 mg per day
  • Thioridazine from about 200 to about 600 mg per day; Fluphenazine: from about 2 to about 5 mg per day; Trifluoperazine: from about 6 to about 20 mg per day; Perphenazine: from about 8 to about 40 mg per day; Clozapine: from about 300 to about 600 mg per day:
  • Haloperidol from about 1 to about 20 mg per day; Loxapine: from about 60 to about 100 mg per day; Molindone: from about 15 to about 225 mg per day; Thiothixene: from about 20 to about 30 mg per day; Risperidone: from about 4 to about 20 mg per day;
  • Seroquel from about 15 to about 750 mg per day; and Olanzapine: from about 10 to about 20 mg per day.
  • compositions according to the present invention comprise a combination according to the invention together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents.
  • the carriers must be acceptable in the sense of being compatible with the other ingredients in the formula.
  • a combination of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4- dioxino[2,3-e]indol-8-one and an antipsychotic agent may conveniently be presented as a pharmaceutical formulation in a unitary dosage form.
  • a convenient unitary dosage formulation contains the active ingredients in amounts from 0.1 mg to 1 g each, for example 5 mg to 100 mg.
  • Typical unit doses may, for example, contain about 0.5 to about 100 mg (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4- dioxino[2,3-e]indol-8-one, and preferably about 1 mg to about 50 mg of (S)-2- (benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one .
  • compositions may be prepared as "patient packs" containing the whole course of treatment in a single package, usually a blister pack.
  • Patient packs have an advantage over traditional prescriptions, where a pharmacist divides a patient's supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in traditional prescriptions.
  • the inclusion of a package insert has been shown to improve patient compliance with the physician's instructions.
  • a patient pack comprising at least one active ingredient of the combination of the invention and an information insert containing directions on the use of the combination of the invention.
  • Formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.
  • the formulations may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al., Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and their Manufacture).
  • Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
  • accessory ingredients include those conventional in the art, such as, fillers, binders, diluents, disintegrants, lubricants, colorants, flavouring agents and wetting agents.
  • Formulations suitable for oral administration may be presented as discrete units such as pills, tablets or capsules each containing a predetermined amount of active ingredient; as a powder or granules; as a solution or suspension.
  • the active ingredient may also be present as a bolus or paste, or may be contained within liposomes.
  • Formulations for rectal administration may be presented as a suppository or enema.
  • suitable formulations include aqueous and non- aqueous sterile injection.
  • the formulations may be presented in unit-dose or multi- dose containers, for example, sealed vials and ampoules, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water prior to use.
  • Formulations suitable for administration by nasal inhalation include fine dusts or mists which may be generated by means of metered dose pressurized aerosols, nebulisers or insufflators.
  • side effects caused by treatment with haloperidol are influenced by concommitant treatment with (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one.
  • Tests for reversal of haloperidol-induced catalepsy in rats were conducted according to a variation of the methods of Svensson et al., Neuropharmacology, 1993, 32: 1037-1045. Rats (200 - 250g) were transported from the colony room to the experimental room and held there for the duration of the experiment. Haloperidol, dissolved in 0.25% Tween 80®, was administered to all animals at a dose of 3 mg/kg i.p.
  • Figure 1 is a schematic representation of the effect of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) on haloperidol- induced catalepsy in rats at 60 minutes after drug treatment, the time point of greatest reversal.
  • the data are means + SEM.
  • a dose-dependent decrease in time spent in catalepsy position was observed.
  • a MED of 0.3 mg/kg and an ED 50 of 0.08 mg/kg were calculated from these results.
  • FIG. 1 is a schematic representation of the ability of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) to induce catalepsy in rats.
  • the data are means + SEM.
  • mice 25 - 30g were transported from the colony room to the experimental room and held there for the duration of the experiment. The animals were habituated in the locomotor test chambers (an open field 8 X 8 in.) for 60 min prior to testing. Following the habituation period, d-amphetamine (2.5 mg/kg i.p., dissolved in distilled water) was administered to all animals. Fifteen minutes later, test compounds dissolved in 0.25% Tween 80® were administered s.c. at 8 dose levels to 8 mice per dose level. Control groups, assessed simultaneously with drug-treated groups, received vehicle at equal volumes (10 ml/kg). Immediately after administration of the test compound, animals were placed individually into the locomotor activity chambers. Activity was monitored for
  • Figure 3 is a schematic representation of the effect of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) to reverse d-amphetamine induced hyperactivity in mice.
  • the data are expressed as a percentage of the activity level observed in mice treated with d-amphetamine alone and are presented as means + SEM.
  • a dose-dependent decreased in d-amphetamine-induced hyperactivity was observed.
  • An ED 50 of 0.002 mg/kg was calculated from these results.
  • compositions of the present invention reduce side effects induced by haloperidol as modeled by catelepsy, while not diminishing the ability of haloperidol to treat positive symptoms of schizophrenia as modeled by the amphetamine-induced hyperactivity.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Therapeutic combinations useful in the treatment or prevention of psychotic disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of prevention disorders are provided.

Description

NEW THERAPEUTIC COMBINATIONS OF (S)-2-(BENZYLAMINO-
METHYL)-2,3,8,9,-TETRAHYDRO-7H-l,4-DIOXINO[2,3-e]INDOL-8-ONE
AND NEUROLEPTICS FOR THE TREATMENT OR PREVENTION OF
PSYCHOTIC DISORDERS
Field of the Invention
The present invention relates to therapeutic combinations of (S)-2- (benzylaminomethyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one, a partial agonist of the dopamine D2/D3 receptors, and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of psychotic disorders.
Background of the Invention Psychoses are serious mental illnesses characterized by defective or lost contact with reality. These disorders are characterized by a variety of symptoms which are classified as positive symptoms (disordered thought, hallucinations, and delusions), negative symptoms (social withdrawal and unresponsiveness), and cognitive deficits. Neuroleptics or antipsychotics can be used to treat schizophrenia and other related psychotic disorders by blocking the dopaminergic neurotransmission in the central nervous system. Neuroleptics are used widely to treat the "positive" symptoms of schizophrenia. However, many of these drugs are not considered to be effective for the treatment of "negative" symptoms of schizophrenia and may in fact exacerbate these symptoms because of the dopaminergic blockade associated with their mechanism of action. Cognitive deficits associated with schizophrenia, such as distractability, and executive skills such as a working memory and ability to plan, are also believed to be negatively effected by the blockade of dopamine receptors.
In addition, these neuroleptics have important side effects such as akathisia, dystonia, Parkinsonism dyskinesia and late dyskinesia and the like, which are caused by blocking the dopaminergic neurotransmission. Anticholinergic agents such as Cogentin®, have been used to reduce Parkinson-like side effects, but also cause side effects such as mental and/or physical impairment, tachycardia, dysuria and gastrointestinal symptoms.
Some partial dopamine agonists with relatively high intrinsic activity have been shown to have effectiveness against the negative symptoms of schizophrenia. It has been hypothesized that in this respect, some intrinsic activity is desirable to optimize the treatment of negative symptoms while minimizing side effects.
Lindenmayer, J.P., Ada Psychiatrica Scand. 1995:91 (supp. 388): 15-19.
However, with increasing intrinsic activity, levels of dopamine transmission are higher and thus, positive symptoms may be less effectively treated.
It has been found that partial dopamine agonists having moderate to high intrinsic activity, such as preclamol, pramipexole and terguride have been useful in reversing the side effects of traditional neuroleptics. These reports indicate that higher intrinsic activity leads to greater effectiveness in alleviating motor dysfunction-related side effects. Svensson, et al., Neuropharmacology, 32(10): 1037- 1045 (1993).
New combination drug therapies may be useful for treatment of patients. It is greatly desired to optimize the beneficial properties of both drugs, while minimizing the side effects associated with the drugs when given alone. Applicants have found useful therapeutic combination for the treatment of psychotic disorders.
Brief Description of the Drawings
Figure 1 is a schematic representation of the effect of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) on haloperidol- induced catalepsy in rats at 60 minutes after drug treatment, the time point of greatest reversal as measured by seconds spent in catelepsy over a dose range of 0.003 to 3 mg/kg s.c. of agent. The data are means + SEM.
Figure 2 is a schematic representation of the ability of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) to induce catalepsy in rats as measured by seconds spent in catelepsy over a dose range of 0.003 to 3 mg/kg s.c. of agent. The data are means + SEM. Figure 3 is a schematic representation of the effect of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) to reverse d-amphetamine induced hyperactivity in mice. The data are expressed as a percentage of the activity level (horizontal activity counts) observed in mice treated with d-amphetamine alone for eight doses ranging from 0.0001 to 1 mg kg s.c. of agent. The data are presented as means + SEM.
Detailed Description of the Invention
In accordance with the present invention is provided a composition comprising (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]- indol-8-one, or pharmaceutical salts thereof, and one or more antipsychotic agents.
(S)-2-(Benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol- 8-one , a D2 partial agonist, is disclosed in U.S. Patent No. 5,756,532. (S)-2-(Benzyl- amino-methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one, as used herein, includes pharmaceutical salts thereof, unless otherwise indicated.
Pharmaceutically acceptable salts include acid addition salts such as hydrochloric, fumaric, maleic, citric or succinic.
The term antipsychotic agent or neuroleptic agent includes those antipsychotics which work as a full antagonist of the dopamine D2 receptor and include both typical and atypical antipsychotics. Representative antipsychotic agents that are commercially available or known to those skilled in the art and include, but are not limited to:
Chlorpromazine, or 2-chloro-N,N-dimethyl- 1 OH-phenothiazine- 10-propan- amine, is described in U.S. Patent No. 2,645,640, which is incorporated by reference herein in its entirety.
Mesoridazine, or 10-[2-(l-methyl-2-piperidinyl)ethyl]-2-(methylsulfinyl)- 1 OH-phenothiazine is described in U.S. Patent No. 3,084,161, which is incorporated by reference herein in its entirety.
Thioridazine, or 10-[2-(l-methyl-2-piperidinyl)ethyl]-2-(methylthio)-10H- phenothiazine is described in Collect. Czech. Chem. Commun., 1990,55,1586-1601, which is incorporated by reference herein in its entirety. Fluphenazine, or 4- [3- [2-(trifluoromethyl)- 1 OH-phenothiazin- 10-yl]propyl]- 1 - piperazineethanol is described in GB 829,246, which is incorporated by reference herein in its entirety.
Trifluoperazine, or 10- [3-(4-methyl- 1 -piperazinyl)-propyl]-2-(trifluoro- methyl)- 1 OH-phenothiazine is described in GB 813,861 which is incorporated by reference herein in its entirety.
Perphenazine, or 4-[3-(2-chloro-10H-phenothiazin-l-yl)propyl]-l-piperazine- ethanol, is described in U.S. Patent No. 2,766,235, which is incorporated by reference herein in its entirety. Clozapine, or 8-chloro-l l-(4-methyl-l-piperazinyl)-5H-dibenzo[b,e]-[l,4]- diazepine is described in U.S. Patent No. 3,539,573, which is incorporated by reference herein in its entirety.
Haloperidol, or 4-[4-(4-chlorophenyl)-4-hydroxy-l-piperidinyl]-l-(4-fluoro- phenyl)-l-butanone is described in U.S. Patent No. 3,438,991, which is incorporated by reference herein in its entirety.
Loxapine, or 2-chloro- 11 -(4-methyl- 1 -piperazinyl)-dibenz[b,f] [ 1 ,4]oxazepine is described in U.S. Patent No. 3,546,226, which is incorporated by reference herein in its entirety.
Molindone, or 3-ethyl- 1 ,5 ,6,7-tetrahydro-2-methyl-5-(4~morpholinylmethyl)- 4H-indol-4-one, is described in U.S. Patent No. 3,491,093, which is incorporated by reference herein in its entirety.
Thiothixene, or N,N-dimethyl-9-[3-(4-methyl- 1 -piperazinyl)-propylidene-9H- thioxanthene-2-sulfanamide is described in U.S. Patent No. 3,310,553, which is incorporated by reference herein in its entirety. Sulphide, or 5-(aminosulfonyl)-N-[(l-ethyl-2-pyrolidinyl)methyl]-2-meth- oxybenzamide, is described in U.S. Patent No. 3,342,826, which is incorporated by reference herein in its entirety.
Amisulpiride, or 4-amino-N-[(l-ethyl-2-pyrrolidin-yl)methyl]-5-(ethyl- sulfonyl)-2-methoxybezamide, is described in U.S. Patent No. 4,401,822, which is incorporated by reference herein in its entirety.
Risperidone, or 3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)piperidino]-ethyl]- imidazolidin-2-one, is described in U.S. Patent No. 4,804,663, which is incorporated by reference herein in its entirety. Seroquel, or 1 l-[4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyl]dibenzo[b,f]- [l,4]thiazepine, preparation is described in EP 240228, which is incorporated by reference herein in its entirety.
Olanzapine, or 2-methyl-4-(4-methyl- 1 -piperazinyl)- 10H-thieno[2,3-b] [1,5]- benzodiazepine, is described in U.S. Patent No. 5,229,382, which is incorporated by reference herein in its entirety.
Administration of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4- dioxino[2,3-e]indol-8-one in combination with one or more antipsychotic agents is useful for the treatment or prevention of psychotic disorders associated with altered neurotransmission activity of the dopaminergic system in the central nervous system such as schizophrenia, schizoaffective disorder, acute mania, and depression with psychotic features, while eliminating or minimizing certain side affects associated with said antipsychotics when taken alone such as akathisia, dystonia, Parkinsonism dyskinesia and late dyskinesia and the like. This invention also provides a product comprising (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one and an antipsychotic agent as a combined preparation for simultaneous, separate or sequential administration to treat a patient suffering from a psychotic disorder.
Combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4-di- oxino[2,3-e]indol-8-one and one or more antipsychotics, hereinafter referred to as "combinations" may be administered simultaneously, in the same or different pharmaceutical formulation, or sequentially. Of course the timing of the sequential administration should preserve the advantageous effects of the combination and said timing can be determined by a skilled practitioner.
A therapeutically acceptable amount of the combination will be understood to be an amount which treats, inhibits, prevents or ameliorates one or more symptoms of the psychotic disorder in question, preferably with fewer side effects than those associated with the administration of the antipsychotic agent alone. The dosages of each of the drugs in the combination must be determined by a physician and will depend upon the specific psychotic disorder, as well as the size, age and response pattern of the patient. Dosage guidelines are provided here. For the combination, the dosage guideline for each of the drugs of the combination would be considered.
In general, suitable doses of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro- 7H-l,4-dioxino[2,3-e]indol-8-one, range from about 0.5 mg per day to about 100 mg per day, and more preferably from about 1 to about 50 mg per day.
A suitable dose of antipsychotic agent will be in the range recommended by the manufacturer. The following guidelines are provided for some preferred antipsychotics of the present invention:
Chlorpromazine: from about 300 to about 800 mg per day; Mesoridazine: from about 100 to about 400 mg per day;
Thioridazine: from about 200 to about 600 mg per day; Fluphenazine: from about 2 to about 5 mg per day; Trifluoperazine: from about 6 to about 20 mg per day; Perphenazine: from about 8 to about 40 mg per day; Clozapine: from about 300 to about 600 mg per day:
Haloperidol: from about 1 to about 20 mg per day; Loxapine: from about 60 to about 100 mg per day; Molindone: from about 15 to about 225 mg per day; Thiothixene: from about 20 to about 30 mg per day; Risperidone: from about 4 to about 20 mg per day;
Seroquel: from about 15 to about 750 mg per day; and Olanzapine: from about 10 to about 20 mg per day.
While it is possible for the active ingredients of the combination to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation. Pharmaceutical formulations according to the present invention comprise a combination according to the invention together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents. The carriers must be acceptable in the sense of being compatible with the other ingredients in the formula. When the individual components of the combination are administered separately, they are generally each presented as a pharmaceutical formulation. A combination of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4- dioxino[2,3-e]indol-8-one and an antipsychotic agent may conveniently be presented as a pharmaceutical formulation in a unitary dosage form. A convenient unitary dosage formulation contains the active ingredients in amounts from 0.1 mg to 1 g each, for example 5 mg to 100 mg. Typical unit doses may, for example, contain about 0.5 to about 100 mg (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4- dioxino[2,3-e]indol-8-one, and preferably about 1 mg to about 50 mg of (S)-2- (benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one .
Pharmaceutical formulations may be prepared as "patient packs" containing the whole course of treatment in a single package, usually a blister pack. Patient packs have an advantage over traditional prescriptions, where a pharmacist divides a patient's supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in traditional prescriptions. The inclusion of a package insert has been shown to improve patient compliance with the physician's instructions.
It will be understood that the administration of the combination of the invention by means of a single patient pack, or patient packs of each formulation, with a package insert directing the patient to the correct use of the invention is a desirable additional feature of this invention. According to a further aspect of the invention, there is provided a patient pack comprising at least one active ingredient of the combination of the invention and an information insert containing directions on the use of the combination of the invention.
Formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al., Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and their Manufacture). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. Such accessory ingredients include those conventional in the art, such as, fillers, binders, diluents, disintegrants, lubricants, colorants, flavouring agents and wetting agents.
Formulations suitable for oral administration may be presented as discrete units such as pills, tablets or capsules each containing a predetermined amount of active ingredient; as a powder or granules; as a solution or suspension. The active ingredient may also be present as a bolus or paste, or may be contained within liposomes.
Formulations for rectal administration may be presented as a suppository or enema. For parenteral administration, suitable formulations include aqueous and non- aqueous sterile injection. The formulations may be presented in unit-dose or multi- dose containers, for example, sealed vials and ampoules, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water prior to use. Formulations suitable for administration by nasal inhalation include fine dusts or mists which may be generated by means of metered dose pressurized aerosols, nebulisers or insufflators.
The compounds of the combination of the present invention may be obtained in a conventional manner by methods known in the art. The following examples are intended for illustration only and are not intended to limit the scope of the invention in any way.
As shown by the following examples, side effects caused by treatment with haloperidol are influenced by concommitant treatment with (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one.
EXAMPLE 1
Tests for reversal of haloperidol-induced catalepsy in rats were conducted according to a variation of the methods of Svensson et al., Neuropharmacology, 1993, 32: 1037-1045. Rats (200 - 250g) were transported from the colony room to the experimental room and held there for the duration of the experiment. Haloperidol, dissolved in 0.25% Tween 80®, was administered to all animals at a dose of 3 mg/kg i.p. Sixty minutes later, (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4- dioxino[2,3-e]indol-8-one, also dissolved in 0.25% Tween 80®, was administered s.c. at 4 dose levels to 6 male Sprague-Dawley rats per dose level. A control group, assessed simultaneously with (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4- dioxino[2,3-e]indol-8-one treated groups, received a vehicle (VEH) injection of 0.25% Tween 80® at equal volumes (1 ml/kg). Animals were assessed for catalepsy at 30, 60, 90 and 120 minutes after drug administration by placing the animal's forepaws on a wooden cube (8x8x8cm). The time that the animal remained with at least one of the forepaws on the cube was measured (maximum = 60 sec). The righting reflex was then tested and used to discard sedated subjects. Data were analyzed using a two-factor analysis of variance with one repeated measure. A subsequent least significant difference from control test (p < 0.05) was used to determine the minimal effective dose (MED) for reversing haloperidol-induced catalepsy and to determine time of onset. A trend test was then used to determine at which time points (if any) there was a dose-related effect. From these time points the point showing the greatest degree of reversal (having the lowest catalepsy scored) was used to calculate ED50 (dose producing 50% reduction in maximal response) and 95% confidence intervals. This was done using nonlinear regression analysis followed by inverse prediction.
Figure 1 is a schematic representation of the effect of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) on haloperidol- induced catalepsy in rats at 60 minutes after drug treatment, the time point of greatest reversal. The data are means + SEM. As shown in the figure, a dose-dependent decrease in time spent in catalepsy position was observed. A MED of 0.3 mg/kg and an ED50 of 0.08 mg/kg were calculated from these results.
EXAMPLE 2
Tests for cataleptogenic potential of (S)-2-(benzylamino-methyl)-2,3,8,9- tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one in rats were conducted by a method similar to that described in Example 1, except that haloperidol was not administered. Figure 2 is a schematic representation of the ability of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) to induce catalepsy in rats. The data are means + SEM. As shown in the figure, there is a lack of ability of the agent to induce significant catalepsy in rats over a dose range of 0.003 to 3 mg/kg s.c. at 60 min post dosing. Similar results were observed at the other time points tested.
EXAMPLE 3
The ability to antagonize amphetamine-induced hyperlocomotion was tested according to a modified version of the methods of Riffee and Wilcox, Psychopharmacology, 1985, 85:97-101. Mice (25 - 30g) were transported from the colony room to the experimental room and held there for the duration of the experiment. The animals were habituated in the locomotor test chambers (an open field 8 X 8 in.) for 60 min prior to testing. Following the habituation period, d-amphetamine (2.5 mg/kg i.p., dissolved in distilled water) was administered to all animals. Fifteen minutes later, test compounds dissolved in 0.25% Tween 80® were administered s.c. at 8 dose levels to 8 mice per dose level. Control groups, assessed simultaneously with drug-treated groups, received vehicle at equal volumes (10 ml/kg). Immediately after administration of the test compound, animals were placed individually into the locomotor activity chambers. Activity was monitored for
30 minutes with lights on using Omnitech Digiscan® (Columbus, Ohio) infrared monitors. Each infrared beam break was counted by the automated system and totaled at 10 minute intervals. Horizontal activity counts collected between 10 and 20 min after the onset of the test session were subjected to a one-way analysis of variance followed by Student-Newman-Keuls test (p < 0.05) to determine doses which were effective at antagonizing d-amphetamine-induced hyperlocomotion relative to the vehicle-treated control group. Mean horizontal activity counts were analyzed by nonlinear regression followed by inverse prediction to calculate the ED50 (dose producing 50% reduction in activity) and 95% confidence intervals (CI) as well as slope and minimum activity level.
Figure 3 is a schematic representation of the effect of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one (agent) to reverse d-amphetamine induced hyperactivity in mice. The data are expressed as a percentage of the activity level observed in mice treated with d-amphetamine alone and are presented as means + SEM. As shown in the figure, a dose-dependent decreased in d-amphetamine-induced hyperactivity was observed. An ED50 of 0.002 mg/kg was calculated from these results.
Thus, compositions of the present invention reduce side effects induced by haloperidol as modeled by catelepsy, while not diminishing the ability of haloperidol to treat positive symptoms of schizophrenia as modeled by the amphetamine-induced hyperactivity.

Claims

1. A composition comprising (S)-2-(benzylamino-methyl)-2,3,8,9-tetra- hydro-7H-l,4-dioxino[2,3-e]indol-8-one and an antipsychotic agent.
2. A pharmaceutical composition comprising (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one, an antipsychotic agent, and one or more pharmaceutical carriers therefor.
3. A pharmaceutical composition for treating a patient suffering from a psychotic disorder comprising an effective amount of (S)-2-(benzylamino-methyl)- 2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one, in combination with an effective amount of an antipsychotic agent.
4. A composition according to any one of Claims 1 to 3 wherein the antipsychotic agent is an atypical antipsychotic.
5. A composition according to any one of Claims 1 to 3 wherein the antipsychotic agent is a typical antipsychotic.
6. A composition according to any one of Claims 1 to 3 wherein the antipsychotic agent is selected from chlorpromazine, mesoridazine, thioridazine, fluphenazine, trifluoperazine, peφhenazine, clozapine, haloperidol, loxapine, molindone, thiothixene, risperidone, seroquel, and olanzapine.
7. A composition according to any one of Claims 1 to 6 wherein the composition is adapted for oral administration.
8. A composition according to any one of Claims 1 to 7 wherein the composition is adapted to administer the antipsychotic in the amount of about 10 mg to about 1000 mg per day.
9. A method of treating a patient suffering from a psychotic disorder comprising administering to said patient an effective amount of (S)-2-(benzylamino- methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one, in combination with an effective amount of an antipsychotic agent.
10. The method of Claim 9 wherein the antipsychotic agent is an atypical antipsychotic.
11. The method of Claim 9 wherein the antipsychotic agent is a typical antipsychotic.
12. The method of Claim 9 wherein the antipsychotic agent is selected from the group consisting of chloφromazine, mesoridazine, thioridazine, fluphenazine, trifluoperazine, peφhenazine, clozapine, haloperidol, loxapine, molindone, thiothixene, risperidone, seroquel, and olanzapine.
13. The method of any one of Claims 9 to 12 wherein administration of the compounds is oral.
14. The method of Claim 9 wherein the patient is suffering from schizophrenia.
15. The method of Claim 9 wherein the patient is suffering from schizoaffective disorder.
16. The method of Claim 9 wherein the patient is suffering from depression.
17. The method of Claim 9 wherein the antipsychotic is administered in the amount of about 10 mg to about 1000 mg per day.
18. A product comprising (S)-2-(benzylaminomethyl)-2,3,8,9-tetrahydro- 7H-l,4-dioxino[2,3-e]indol-8-one and an antipsychotic agent as a combined preparation for simultaneous, separate or sequential administration to treat a patient suffering from a psychotic disorder.
19. A product according to Claim 18 wherein the antipsychotic agent is an atypical antipsychotic.
20. A product according to Claim 18 wherein the antipsychotic agent is a typical antipsychotic.
21. A product according to Claim 18 wherein the antipsychotic agent is selected from chloφromazine, mesoridazine, thioridazine, fluphenazine, trifluoperazine, peφhenazine, clozapine, haloperidol, loxapine, molindone, thiothixene, risperidone, seroquel, and olanzapine.
22. A product according to any one of Claims 18 to 21 which is adapted for oral administration.
23. A product according to Claim 18 for treating schizophrenia.
24. A product according to Claim 18 for treating schizoaffective disorder.
25. A product according to Claim 18 for treating depression.
26. A patient pack comprising at least one active ingredient selected from (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]indol-8-one and an antipsychotic agent, and comprising an information insert containing directions on the use of the active ingredient or active ingredients in a combination comprising (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-l,4-dioxino[2,3-e]- indol-8-one and an antipsychotic.
EP00982461A 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics Withdrawn EP1235570A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US458607 1983-01-17
US45860799A 1999-12-10 1999-12-10
PCT/US2000/033060 WO2001041750A2 (en) 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics

Publications (1)

Publication Number Publication Date
EP1235570A2 true EP1235570A2 (en) 2002-09-04

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00982461A Withdrawn EP1235570A2 (en) 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics

Country Status (20)

Country Link
EP (1) EP1235570A2 (en)
JP (1) JP5557409B2 (en)
KR (1) KR100772854B1 (en)
CN (1) CN1230164C (en)
AR (1) AR026756A1 (en)
AU (1) AU784211B2 (en)
BR (1) BR0016168A (en)
CA (1) CA2396351C (en)
CZ (1) CZ20021880A3 (en)
EA (1) EA005002B1 (en)
HK (1) HK1045942A1 (en)
HU (1) HUP0203309A3 (en)
IL (2) IL149669A0 (en)
MX (1) MXPA02005649A (en)
NO (1) NO20022739D0 (en)
NZ (1) NZ519381A (en)
PL (1) PL355292A1 (en)
TW (1) TWI222864B (en)
WO (1) WO2001041750A2 (en)
ZA (1) ZA200205484B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095292A1 (en) 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
EP1856126A2 (en) 2005-02-17 2007-11-21 Wyeth a Corporation of the State of Delaware Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
EP2633868A1 (en) * 2008-02-13 2013-09-04 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
SMT202200332T1 (en) * 2020-05-04 2022-09-14 Bioprojet Pharma Use of dopamine d3 partial agonists for treating central nervous system disorders
GB202014184D0 (en) 2020-09-09 2020-10-21 Johnson Matthey Plc Modifed catalyst supports and catalysts supported thereon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (en) * 1995-03-16 1999-12-06 大塚製薬 株式会社 Method for producing carbostyril derivative
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XP025567200 *

Also Published As

Publication number Publication date
PL355292A1 (en) 2004-04-05
AU1949001A (en) 2001-06-18
CA2396351A1 (en) 2001-06-14
NO20022739L (en) 2002-06-07
WO2001041750A3 (en) 2002-02-14
CN1409633A (en) 2003-04-09
HUP0203309A2 (en) 2003-01-28
TWI222864B (en) 2004-11-01
NO20022739D0 (en) 2002-06-07
NZ519381A (en) 2004-04-30
CZ20021880A3 (en) 2002-08-14
MXPA02005649A (en) 2004-09-10
HUP0203309A3 (en) 2004-12-28
HK1045942A1 (en) 2002-12-20
ZA200205484B (en) 2003-12-31
AU784211B2 (en) 2006-02-23
CA2396351C (en) 2009-11-10
IL149669A (en) 2006-06-11
KR20030016207A (en) 2003-02-26
JP2003516350A (en) 2003-05-13
EA005002B1 (en) 2004-10-28
JP5557409B2 (en) 2014-07-23
IL149669A0 (en) 2002-11-10
AR026756A1 (en) 2003-02-26
KR100772854B1 (en) 2007-11-02
BR0016168A (en) 2002-08-20
CN1230164C (en) 2005-12-07
WO2001041750A2 (en) 2001-06-14
EA200200656A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
EP1994932A1 (en) Use of N-desmethylclozapine to treat human psychosis
US20070238725A1 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
US20090258084A1 (en) Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia
US6350773B1 (en) Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
ZA200205161B (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone.
CA2396351C (en) New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
CA2649597A1 (en) Mono and combination therapy of m1/m4 agonist (sabcomeline) for treatment of negative symptoms of schizophrenia
AU2004246820B2 (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight
CA2649590A1 (en) Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome
Cheng et al. Dopamine hypothesis
MXPA05013580A (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020527

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020527;LT PAYMENT 20020527;LV PAYMENT 20020527;MK;RO PAYMENT 20020527;SI PAYMENT 20020527

17Q First examination report despatched

Effective date: 20050104

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100407

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1045942

Country of ref document: HK